Randomized controlled single‐blinded clinical trial of functional voice outcome after vascular targeting KTP laser microsurgery of early laryngeal cancer

6533b7d7fe1ef96bd126850b

RESEARCH PRODUCT

Randomized controlled single‐blinded clinical trial of functional voice outcome after vascular targeting KTP laser microsurgery of early laryngeal cancer

Julian Künzel Katharina Eder Lara N. Pfisterer Sebastian Strieth Benjamin Philipp Ernst D Hirth Ina Both

subject

Male Microsurgery Time Factors medicine.medical_treatment Lasers Solid-State 0302 clinical medicine Clinical endpoint Single-Blind Method Prospective Studies Transoral laser microsurgery 030223 otorhinolaryngology Early Detection of Cancer Aged 80 and over Middle Aged Treatment Outcome 030220 oncology & carcinogenesis Carcinoma Squamous Cell Original Article Female Laser Therapy medicine.medical_specialty CO2 laser Voice Quality T1 glottic cancer Voice Handicap Index (VHI‐30)Statistics Nonparametric 03 medical and health sciences local control rate medicine Humans Neoplasm Invasiveness Voice Handicap Index Laryngeal Neoplasms Aged Neoplasm Staging business.industry Carcinoma in situ Reproducibility of Results Cancer Original Articles Recovery of Function medicine.disease Surgery Clinical trial Radiation therapy angiolytic therapy Otorhinolaryngology Dysplasia Lasers Gas business Follow-Up Studies

description

Abstract Background Local control rate (LCR) of early glottic cancer is high after radiation therapy or transoral laser microsurgery (TLM). The aim of this study was to investigate functional voice outcome after TLM using a microvessel‐ablative potassium‐titanyl‐phosphate (KTP) laser in comparison with a gold standard cutting CO2 laser. Methods The primary end point of this prospective, randomized, single‐blinded, clinical phase II study with control group was voice outcome during a follow‐up of 6 months assayed by Voice Handicap Index (VHI‐30)‐questionnaires in patients with unilateral high‐grade dysplasia, carcinoma in situ or early glottic cancer undergoing TLM‐KTP (n = 8) or TLM‐CO2 (n = 12). The secondary end point was LCR. Results Starting from the 9‐week‐follow‐up visit, TLM‐KTP yielded significantly reduced VHI scores compared to TLM‐CO2. No relapse occurred after TLM‐KTP in contrast to one recurrence after TLM‐CO2 within 6 months. Conclusion Multicenter phase II or III studies on voice outcome or local control rate after TLM‐KTP in early glottic cancer are warranted enrolling larger patient cohorts.

year	journal	country	edition	language
2019-01-31	Head & Neck

https://doi.org/10.1002/hed.25474